Basic Information
| LncRNA/CircRNA Name | FEZF1-AS1 |
| Synonyms | NR_036484 |
| Region | GRCh38_7:122303658-122310077 |
| Ensemble | ENSG00000230316 |
| Refseq | NR_036484 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, RNAi, Western blot, RIP, ChIP, MTT assay etc. |
| Sample | gastric cancer tissues, cell lines (MGC-803, SGC-7901, AGS) |
| Expression Pattern | up-regulated |
| Function Description | FEZF1-AS1 was overexpressed in gastric cancer. Further experiments revealed that knockdown FEZF1-AS1 significantly inhibited gastric cancer cells proliferation by inducing G1 arrest and apoptosis, whereas endogenous expression FEZF1-AS1 promoted cell growth. Additionally, RIP assay and RNA-pulldown assay evidenced that FEZF1-AS1 could epigenetically repress the expression of P21 via binding with LSD1, the first discovered demethylase. |
| Pubmed ID | 28209170 |
| Year | 2017 |
| Title | LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. |
External Links
| Links for FEZF1-AS1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |